Lantus Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising prevalence of diabetes globally, advancements in insulin formulation science, widespread clinical acceptance of basal insulin, expansion of outpatient diabetes care, improved patient adherence tools.

The growth in the forecast period can be attributed to growing competition from biosimilar insulins, increasing focus on personalized insulin therapy, expansion of digital diabetes management tools, rising demand for cost-effective insulin options, continued innovation in insulin delivery. Major trends in the forecast period include increasing adoption of long-acting insulin analogues, expansion of diabetes management programs, growing preference for once-daily insulin regimens, enhanced focus on glycemic stability, rising use of pre-filled insulin delivery devices.

The rising prevalence of diabetes is anticipated to drive the growth of the lantus market moving forward. Diabetes is a chronic condition where the body either produces insufficient insulin or cannot utilize the insulin it produces effectively, leading to elevated blood sugar levels. The growing incidence of diabetes can be attributed to factors like sedentary lifestyles, poor eating habits, increasing obesity rates, genetic factors, and an aging population. Lantus helps manage diabetes by providing long-lasting, consistent blood sugar control for up to 24 hours, minimizing glucose fluctuations and enabling patients to maintain stable glucose levels with fewer injections. For example, in March 2024, the Office for Health Improvement and Disparities, a UK-based government agency, reported that by March 2023, the percentage of individuals with type 1 diabetes in England who received 8 care processes at GP practices participating in the NDA rose to 43.8%, up from 35.2% in 2022. As a result, the growing prevalence of diabetes is contributing to the expansion of the lantus market.

The increasing geriatric population is also expected to drive the growth of the lantus market. The geriatric population refers to individuals aged 65 and older, often considered in research and services addressing health, social, and economic challenges related to aging. The rise in the geriatric population is due to higher life expectancy, improved healthcare systems, and declining fertility rates globally. Lantus (insulin glargine) supports the geriatric population by providing long-lasting blood sugar regulation, reducing the risk of complications associated with hyperglycemia in older adults with diabetes. For instance, in July 2024, the UK Parliament's House of Commons Library reported that in 2022, the UK had 12.7 million people aged 65 or older, making up 19% of the total population. By 2072, this figure is projected to increase to 22.1 million, or 27% of the population. As a result, the rising geriatric population is contributing to the growth of the lantus market.

A key trend in the lantus market is the focus on expanding production facilities to increase insulin product output. This expansion typically involves increasing manufacturing capacity, upgrading equipment, and optimizing processes to meet the rising demand for insulin. For example, in August 2024, Sanofi S.A., a France-based pharmaceutical company, invested $1.4 billion (1.3 billion euros) to build a new insulin production facility at its existing site in Frankfurt. This investment is aimed at enhancing Sanofi's insulin production capabilities at its Frankfurt BioCampus, increasing the manufacturing capacity for Lantus and other insulin products. This expansion will help meet the growing demand for diabetes treatments and ensure a stable global supply, reinforcing the company’s commitment to supporting diabetes care worldwide.

Major companies operating in the lantus market are Sanofi S.A.

North America was the largest region in the lantus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lantus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lantus market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the lantus market by increasing costs of imported insulin active ingredients, pen delivery components, sterile packaging materials, and cold-chain logistics services. North America and Europe are most affected due to reliance on global insulin supply chains, while emerging markets face pricing pressures from import dependencies. These tariffs contribute to higher insulin production and distribution costs. However, they are also encouraging regional insulin manufacturing, local filling and packaging operations, and supply chain diversification to improve long-term availability.

The lantus market research report is one of a series of new reports that provides lantus market statistics, including lantus industry global market size, regional shares, competitors with a lantus market share, detailed lantus market segments, market trends and opportunities, and any further data you may need to thrive in the lantus industry. This lantus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lantus is a long-acting insulin formulation, known as insulin glargine, primarily used to manage blood sugar levels in individuals with diabetes. It works by providing a steady and consistent release of insulin over a 24-hour period, helping to mimic the natural insulin secretion of the body and maintain stable blood glucose levels throughout the day.

The main indications for Lantus include the treatment of type 1 diabetes, type 2 diabetes, and the management of hyperglycemia. In type 1 diabetes, Lantus provides a 24-hour basal insulin, which is crucial for maintaining stable blood glucose levels and preventing dangerous fluctuations. It is also used in the management of type 2 diabetes to help control blood sugar when other medications are not sufficient. Lantus is available in various formulations, including injectable solutions for injection and pre-filled pens (Lantus SoloStar), making it easier for patients to administer their doses. Lantus is distributed through multiple channels, including direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, and is used by a wide range of end users, such as hospitals, diabetes clinics, specialty clinics, and home healthcare providers.

The lantus market consists of sales of lantus solostar, lantus vials, and toujeo. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.